• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
The Impact Investor | ESG Investing Blog

The Impact Investor | ESG Investing Blog

Investing for financial return is only part of the equation.

  • ESG Investment Products
    • Best Impact Investing Apps
    • Best ESG Funds
    • Best Socially Responsible Mutual Funds
    • Best BlackRock SRI Funds
    • Best Vanguard ESG Funds
    • Best Sustainable Robo-Advisors
  • ESG Education
    • How to Build a Socially Responsible IRA Portfolio
    • ESG Principles
    • ESG Shareholder Activism
    • Why You Need ESG Investing
    • ESG Investing Trends
    • Social Impact Examples
    • Impact Investing Examples
  • Careers in ESG
    • Best ESG Jobs
    • Best Corporate Responsibility Jobs
    • Environmental Justice Jobs
JOIN

Amgen Inc. ESG Profile (AMGN): Is It Sustainable?

Updated on April 20, 2022

Our posts may contain links from our affiliate partners. This supports helps support the site as we donate 10% of all profits to sustainability organizations that align with our values. However, this does not influence our opinions or ratings. Please read our Terms and Conditions for more information.

Our (AMGN) ESG Review

 Logo
$241.75
SymbolAMGN
Price$241.75
52 Week High 📈$296.67
52 Week Low 📉$223.30
Earnings Per Share đŸ’”12.11
Dividend Yield 🔁3.2132506

Amgen is a biotechnology pioneer and one of the world’s leading independent biotech companies. For more than 40 years, Amgen has pioneered cutting-edge science to transform the practice of medicine. Today, Amgen continues that mission by delivering medicines based on advances in cellular and molecular biology to patients in need worldwide.

The company’s broad portfolio of first-in-class and best-in-class medicines treats serious illnesses in six therapeutic areas: cardiovascular, immunology, oncology, osteoporosis, nephrology and neuroscience. With a deep and broad pipeline of potential new therapies, Amgen remains committed to advancing science to dramatically improve people’s lives.

Amgen’s ESG performance is strong overall, with a particularly good showing on environmental and social issues. On the environment front, Amgen has set ambitious goals for greenhouse gas emissions reductions and renewable energy usage, and has been recognized as one of the world’s top performers on the CDP Climate Change scoring system.

The company has also been recognized as a sector leader on water security by the Carbon Disclosure Project. On social issues, Amgen has been praised for its policies on employee health and safety, and for its efforts to develop medicines for underserved patient populations. However, the company’s score on governance is relatively weak, due in part to concerns about board diversity and executive compensation.

What We Like
  • Has a strong product pipeline with potential blockbuster drugs in development

  • Is a leader in the biotechnology space and has a large market share

  • Has a good ESG rating

What We Don't Like
  • Its recent performance has been lacklustre

  • Faces stiff competition from other companies in the space

AMGN ESG Summary

This is a summary of 's ESG scores from Sustainalytics, MSCI, and ESG Enterprise.

ESG Rating Agency Score or Rating
Sustainalytics 62
MSCI aa
ESG Enterprise BBB

AMGN
Sector: Healthcare
Industry: Drug Manufacturers—General
Employees: 24,200
Business Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. It also has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Company
ExchangeNMS
AddressOne Amgen Center Drive
Go to top

Popular ESG Stocks

Popular ESG Stocks
StockMarketcapIndustryPriceChange %52 Week RangeChart (24H)EPSDividend Yield
NVDA
NVIDIA Corporation
NVDA
692.20BSemiconductors$277.771.44%
2.350.06%
MSFT
Microsoft Corporation
MSFT
2.15TSoftware—Infrastructure$288.301.50%
8.990.92%
BBY
Best Buy Co., Inc.
BBY
17.07BSpecialty Retail$78.273.92%
6.294.67%
ADBE
Adobe Inc.
ADBE
176.77BSoftware—Infrastructure$385.370.91%
10.330.00%
CRM
Salesforce, Inc.
CRM
199.78BSoftware—Application$199.781.62%
0.220.00%
INTU
Intuit Inc.
INTU
125.08BSoftware—Application$445.831.30%
6.950.66%
POOL
Pool Corporation
POOL
13.38BIndustrial Distribution$342.442.18%
18.691.13%
PYPL
PayPal Holdings, Inc.
PYPL
85.92BCredit Services$75.942.08%
2.130.00%
GOOGL
Alphabet Inc.
GOOGL
1.33TInternet Content & Information$103.732.81%
4.690.00%
FSLR
First Solar, Inc.
FSLR
23.23BSolar$217.501.96%
0.430.00%

FAQ

How much is (AMGN) stock?

The current stock price of (AMGN) is $241.75.

What is (AMGN)'s ESG Score?

(AMGN) has an ESG score of 62, BBB, and aa as rated from Sustainalytics, ESG Enterprise, and MSCI, respectively.

Stocks

$241.75
Open $241.43
High $242.40
Close $241.50
Low $239.15
Volume 2,571,130

AMGN ESG Scores đŸŒ±
Sustainalytics 62
MSCI aa
ESG Enterprise BBB

Buy for $241.75

Popular ESG Stocks
Nvidia LogoNVDA
Microsoft LogoMSFT
Best Buy LogoBBY
Adobe LogoADBE
Salesforce LogoCRM
Polar BearPolar Bear on Ice on Ice

Future Generations Will Thank You

Join the newsletter and learn how you can make a invest for financial return and make a positive impact.

JOIN NOW

Footer

About

The Impact Investor is a blog focused on helping retail investors find ESG, socially responsible, and impact investment opportunities through our expert insights, tips, and blog posts.

Resources

  • Best ESG Jobs
  • Best ESG Stocks
  • Best EV Battery Stocks
  • Best ESG Analysis Tools
  • How to Finance Solar Panels

Tools

  • Tesla Charging Calculator
  • Solar Loan Calculator
  • PACE Loan Calculator
  • Electric Bill Calculator

Products

  • Best Investing Apps
  • Best Robo-Advisors
  • Best ESG Funds
  • Vanguard ESG Funds
  • Best Green Credit Cards

Marketplace

  • Community Solar Providers
  • Best Car Insurance for EVs
  • Best Home Solar Systems
  • Best Green Auto Loans

Contact

  • About
  • Contact Us
  • Privacy Policy
  • Disclaimer
  • Facebook
  • Instagram
  • Twitter
  • YouTube

Copyright © 2023 The Impact Investor